Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/drug-resistance-in-anaplastic-lymphoma-kinase-rearranged-lung-cancer-XIzdd0SC49
References (78)
-
(2014)
Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastases AACR annual meeting 2014 -
Ryohei Katayama, Tahsin Khan, C. Benes, E. Lifshits, H. Ebi, V. Rivera, W. Shakespeare, A. Iafrate, J. Engelman, A. Shaw (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALKProceedings of the National Academy of Sciences, 108
-
J. Gainor, L. Dardaei, S. Yoda, L. Friboulet, I. Leshchiner, Ryohei Katayama, I. Dagogo-Jack, S. Gadgeel, Katherine Schultz, Manrose Singh, E. Chin, Melissa Parks, Dana Lee, R. Dicecca, Elizabeth Lockerman, T. Huynh, J. Logan, Lauren Ritterhouse, L. Le, A. Muniappan, S. Digumarthy, C. Channick, C. Keyes, G. Getz, D. Dias-Santagata, R. Heist, J. Lennerz, L. Sequist, C. Benes, A. Iafrate, M. Mino‐Kenudson, J. Engelman, A. Shaw (2016)
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.Cancer discovery, 6 10
-
Y. Cha, B. Cho, H. Kim, H. Lee, H. Shim (2016)
A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 11 5
-
H. Zou, L. Friboulet, D. Kodack, Lars Engstrom, Qiuhua Li, Melissa West, Ruth Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang, Sergei Timofeevski, Ryohei Katayama, D. Dinh, Hieu Lam, Justine Lam, S. Yamazaki, Wenyue Hu, B. Patel, Divya Bezwada, R. Frias, E. Lifshits, Sidra Mahmood, J. Gainor, T. Affolter, P. Lappin, H. Gukasyan, N. Lee, Shibing Deng, R. Jain, T. Johnson, A. Shaw, V. Fantin, T. Smeal (2015)
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.Cancer cell, 28 1
-
S. Anai, M. Takeshita, N. Ando, Yuuki Ikematsu, Shohei Mishima, Koichi Ishida, Kouji Inoue (2016)
A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 11 10
-
G. Hrustanovic, V. Olivas, E. Pazarentzos, Asmin Tulpule, S. Asthana, C. Blakely, R. Okimoto, Luping Lin, Dana Neel, A. Sabnis, Jennifer Flanagan, Elton Chan, M. Varella-Garcia, D. Aisner, A. Vaishnavi, S. Ou, E. Collisson, E. Ichihara, P. Mack, C. Lovly, N. Karachaliou, R. Rosell, J. Riess, R. Doebele, T. Bivona (2015)
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK–positive lung cancerNature Medicine, 21
-
Masamichi Mori, Y. Ueno, S. Konagai, H. Fushiki, I. Shimada, Yutaka Kondoh, Rika Saito, K. Mori, Nobuaki Shindou, T. Soga, H. Sakagami, T. Furutani, Hitoshi Doihara, M. Kudoh, S. Kuromitsu (2014)
The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model MiceMolecular Cancer Therapeutics, 13
-
J. Bilsland, A. Wheeldon, A. Mead, Petr Znamenskiy, Sarah Almond, Kerry Waters, Matthew Thakur, V. Beaumont, T. Bonnert, R. Heavens, P. Whiting, G. Mcallister, I. Muñoz-Sanjuán (2008)
Behavioral and Neurochemical Alterations in Mice Deficient in Anaplastic Lymphoma Kinase Suggest Therapeutic Potential for Psychiatric IndicationsNeuropsychopharmacology, 33
-
W. Sato, N. Fukazawa, O. Nakanishi, M. Baba, Tsuneji Suzuki, O. Yano, M. Naito, T. Tsuruo (1995)
Reversal of multidrug resistance by a novel quinoline derivative, MS-209Cancer Chemotherapy and Pharmacology, 35
-
A. Shaw, E. Felip, T. Bauer, B. Besse, A. Navarro, S. Postel-Vinay, J. Gainor, M. Johnson, J. Dietrich, L. James, J. Clancy, Joseph Chen, J. Martini, A. Abbattista, B. Solomon (2017)
Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trialThe Lancet. Oncology, 18
-
A. Shaw, L. Friboulet, I. Leshchiner, J. Gainor, S. Bergqvist, A. Brooun, B. Burke, Ya-Li Deng, Wei Liu, L. Dardaei, R. Frias, Katherine Schultz, J. Logan, L. James, T. Smeal, Sergei Timofeevski, Ryohei Katayama, A. Iafrate, L. Le, M. McTigue, G. Getz, T. Johnson, J. Engelman (2016)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.The New England journal of medicine, 374 1
-
A. Shaw, T. Kim, L. Crinò, C. Gridelli, K. Kiura, Geoffrey Liu, S. Novello, A. Bearz, O. Gautschi, T. Mok, M. Nishio, G. Scagliotti, D. Spigel, S. Deudon, C. Zheng, Serafino Pantano, P. Urban, C. Massacesi, K. Viraswami-Appanna, E. Felip (2017)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.The Lancet. Oncology, 18 7
-
Ryohei Katayama, T. Sakashita, N. Yanagitani, H. Ninomiya, A. Horiike, L. Friboulet, J. Gainor, N. Motoi, Akito Dobashi, S. Sakata, Y. Tambo, S. Kitazono, Shigeo Sato, S. Koike, A. Iafrate, M. Mino‐Kenudson, Y. Ishikawa, A. Shaw, J. Engelman, K. Takeuchi, M. Nishio, N. Fujita (2015)
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung CancerEBioMedicine, 3
-
M. Soda, S. Takada, K. Takeuchi, Y. Choi, M. Enomoto, Toshihide Ueno, H. Haruta, T. Hamada, Y. Yamashita, Y. Ishikawa, Y. Sugiyama, H. Mano (2008)
A mouse model for EML4-ALK-positive lung cancerProceedings of the National Academy of Sciences, 105
-
L. Crinò, M. Ahn, F. Marinis, H. Groen, H. Wakelee, T. Hida, T. Mok, D. Spigel, E. Felip, M. Nishio, G. Scagliotti, F. Branle, Chetachi Emeremni, M. Quadrigli, Jie Zhang, A. Shaw (2016)
Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK-Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 24
-
Emma Vernersson, N. Khoo, M. Henriksson, G. Roos, R. Palmer, B. Hallberg (2006)
Characterization of the expression of the ALK receptor tyrosine kinase in mice.Gene expression patterns : GEP, 6 5
-
G. Stoica, Angera Kuo, A. Aigner, I. Sunitha, B. Souttou, C. Malerczyk, Dana Caughey, D. Wen, A. Karavanov, A. Riegel, A. Wellstein (2001)
Identification of Anaplastic Lymphoma Kinase as a Receptor for the Growth Factor Pleiotrophin*The Journal of Biological Chemistry, 276
-
P. Mathew, S. Morris, J. Kane, S. Shurtleff, Marcelo Pasquini, N. Jenkins, D. Gilbert, N. Copeland (1995)
Localization of the murine homolog of the anaplastic lymphoma kinase (AlK) gene on mouse chromosome 17.Cytogenetics and cell genetics, 70 1-2
-
T. Seto, K. Kiura, M. Nishio, K. Nakagawa, M. Maemondo, A. Inoue, T. Hida, N. Yamamoto, H. Yoshioka, M. Harada, Y. Ohe, N. Nogami, K. Takeuchi, T. Shimada, Tomohiro Tanaka, T. Tamura (2013)
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study.The Lancet. Oncology, 14 7
-
Tatsushi Kodama, T. Tsukaguchi, M. Hasegawa, Miyuki Yoshida, Kenji Takanashi, O. Kondoh, H. Sakamoto (2014)
Abstract 754: Selective ALK inhibitor alectinib (CH5424802/RO5424802) with potent antitumor activity in models of crizotinib resistance, including intracranial metastasesCancer Research, 74
-
J. Gainor, C. Sherman, K. Willoughby, J. Logan, E. Kennedy, P. Brastianos, A. Chi, A. Shaw (2015)
Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and CeritinibJournal of Thoracic Oncology, 10
-
A. Shaw, J. Engelman (2014)
Ceritinib in ALK-rearranged non-small-cell lung cancer.The New England journal of medicine, 370 26
-
Takaaki Sasaki, J. Koivunen, Atsuko Ogino, M. Yanagita, S. Nikiforow, Wei Zheng, C. Lathan, J. Marcoux, Jinyan Du, K. Okuda, M. Capelletti, T. Shimamura, D. Ercan, Magda Stumpfova, Yun Xiao, S. Weremowicz, M. Butaney, S. Héon, K. Wilner, J. Christensen, M. Eck, Kwok-kin Wong, N. Lindeman, N. Gray, S. Rodig, P. Jänne (2011)
A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.Cancer research, 71 18
-
K. Uchibori, N. Inase, M. Araki, M. Kamada, Shigeo Sato, Y. Okuno, N. Fujita, Ryohei Katayama (2017)
Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancerNature Communications, 8
-
Y. Choi, M. Soda, Y. Yamashita, Toshihide Ueno, Junpei Takashima, T. Nakajima, Y. Yatabe, K. Takeuchi, T. Hamada, H. Haruta, Y. Ishikawa, H. Kimura, T. Mitsudomi, Y. Tanio, H. Mano (2010)
EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.The New England journal of medicine, 363 18
-
Dong-Wan Tiseo, Marcello Ahn, Myung-Ju Reckamp, K. Hansen, Karin Kim, S. Huber, Rudolf West, Howard Groen, Harry Hochmair, J. Maximilian, Dong-Wan Kim, M. Tiseo, M. Ahn, K. Reckamp, K. Hansen, Sang-We Kim, R. Huber, H. West, H. Groen, M. Hochmair, N. Leighl, S. Gettinger, C. Langer, L. Paz-Ares, E. Smit, Edward Kim, W. Reichmann, F. Haluska, D. Kerstein, R. Camidge (2017)
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 22
-
Y. Mossé, M. Laudenslager, L. Longo, K. Cole, A. Wood, E. Attiyeh, M. Laquaglia, Rachel Sennett, Jill Lynch, P. Perri, G. Laureys, F. Speleman, Cecilia Kim, C. Hou, H. Hakonarson, A. Torkamani, N. Schork, G. Brodeur, G. Tonini, E. Rappaport, M. Devoto, J. Maris (2008)
Identification of ALK as a major familial neuroblastoma predisposition geneNature, 455
-
F. Blackhall, D. Camidge, A. Shaw, J. Soria, B. Solomon, T. Mok, V. Hirsh, P. Jänne, Yuankai Shi, Pan‐Chyr Yang, T. Pas, T. Hida, J. Carpeño, S. Lanzalone, A. Polli, S. Iyer, A. Reisman, K. Wilner, Dong-Wan Kim (2017)
Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancerESMO Open, 2
-
S. Morris, M. Kirstein, M. Valentine, K. Dittmer, D. Shapiro, D. Saltman, A. Look (1994)
Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma.Science, 267 5196
-
Ryohei Katayama, Ryohei Katayama, L. Friboulet, S. Koike, Elizabeth Lockerman, Tahsin Khan, J. Gainor, A. Iafrate, K. Takeuchi, M. Taiji, Y. Okuno, N. Fujita, J. Engelman, A. Shaw (2014)
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor AlectinibClinical Cancer Research, 20
-
B. Cho, Dong-Wan Kim, A. Bearz, S. Laurie, M. McKeage, G. Borra, Keunchil Park, Sang-We Kim, M. Ghosn, A. Ardizzoni, E. Maiello, A. Greystoke, R. Yu, K. Osborne, W. Gu, J. Scott, V. Passos, Yvonne Lau, A. Wrona (2017)
ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)Journal of Thoracic Oncology, 12
-
T. Hida, H. Nokihara, M. Kondo, Y. Kim, K. Azuma, T. Seto, Y. Takiguchi, M. Nishio, H. Yoshioka, F. Imamura, K. Hotta, Satoshi Watanabe, K. Goto, M. Satouchi, T. Kozuki, T. Shukuya, K. Nakagawa, T. Mitsudomi, N. Yamamoto, T. Asakawa, Ryoichi Asabe, Tomohiro Tanaka, T. Tamura (2017)
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trialThe Lancet, 390
-
A. Drilon, S. Siena, S. Ou, M. Patel, M. Ahn, Jeeyun Lee, T. Bauer, A. Farago, J. Wheler, Stephen Liu, R. Doebele, L. Giannetta, G. Cerea, G. Marrapese, M. Schirru, A. Amatu, K. Bencardino, L. Palmeri, A. Sartore-Bianchi, A. Vanzulli, S. Cresta, S. Damian, M. Duca, E. Ardini, G. Li, J. Christiansen, K. Kowalski, Ann Johnson, Rupal Patel, D. Luo, E. Chow-Maneval, Zachary Hornby, P. Multani, A. Shaw, F. Braud (2017)
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).Cancer discovery, 7 4
-
C. Lovly, Nerina McDonald, Heidi Chen, S. Ortiz-Cuaran, L. Heukamp, Ying Yan, A. Florin, Luka Ozretić, D. Lim, Lu Wang, Zhao Chen, Xi Chen, P. Lu, P. Paik, R. Shen, Hailing Jin, R. Buettner, S. Ansén, S. Perner, M. Brockmann, M. Bos, J. Wolf, M. Gardizi, Gavin Wright, B. Solomon, P. Russell, Toni-Maree Rogers, Y. Suehara, Monica Red-Brewer, Rudy Tieu, E. Stanchina, Qingguo Wang, Zhongming Zhao, David Johnson, L. Horn, Kwok-kin Wong, Roman Thomas, M. Ladanyi, W. Pao (2014)
Rationale for co-targeting IGF-1R and ALK in ALK fusion positive lung cancerNature medicine, 20
-
D. Costa, Susumu Kobayashi, S. Pandya, W. Yeo, Zhongzhou Shen, Weiwei Tan, K. Wilner (2011)
CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15
-
(2013)
phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials -
S. Bresler, D. Weiser, Peter Huwe, Jin Park, K. Krytska, H. Ryles, M. Laudenslager, E. Rappaport, A. Wood, Patrick McGrady, M. Hogarty, W. London, R. Radhakrishnan, M. Lemmon, Y. Mossé (2014)
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma.Cancer cell, 26 5
-
M. Soda, Y. Choi, M. Enomoto, S. Takada, Y. Yamashita, S. Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, K. Kurashina, H. Hatanaka, M. Bando, S. Ohno, Y. Ishikawa, H. Aburatani, T. Niki, Y. Sohara, Y. Sugiyama, H. Mano (2007)
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 448
-
R. Doebele, Amanda Pilling, D. Aisner, T. Kutateladze, A. Le, A. Weickhardt, K. Kondo, Derek Linderman, L. Heasley, W. Franklin, M. Varella-Garcia, R. Camidge (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung CancerClinical Cancer Research, 18
-
A. Murugan, Mingzhao Xing (2011)
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene.Cancer research, 71 13
-
J. Guan, Ganesh Umapathy, Y. Yamazaki, G. Wolfstetter, Patricia Mendoza, K. Pfeifer, Ateequrrahman Mohammed, Fredrik Hugosson, Hongbing Zhang, A. Hsu, R. Halenbeck, B. Hallberg, R. Palmer (2015)
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinaseeLife, 4
-
Seng Tang, Luan Nguyen, R. Sparidans, E. Wagenaar, J. Beijnen, A. Schinkel (2014)
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridarInternational Journal of Cancer, 134
-
D. Camidge, Y. Bang, E. Kwak, A. Iafrate, M. Varella-Garcia, S. Fox, Gregory Riely, B. Solomon, S. Ou, Dong-Wan Kim, R. Salgia, P. Fidias, J. Engelman, L. Gandhi, P. Jänne, D. Costa, G. Shapiro, P. LoRusso, K. Ruffner, P. Stephenson, Yiyun Tang, K. Wilner, Jeffrey Clark, A. Shaw (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.The Lancet. Oncology, 13 10
-
Ryohei Katayama, A. Shaw, A. Shaw, Tahsin Khan, Tahsin Khan, M. Mino‐Kenudson, B. Solomon, B. Halmos, Nicholas Jessop, J. Wain, Alan Yeo, C. Benes, L. Drew, J. Saeh, K. Crosby, L. Sequist, A. Iafrate, J. Engelman (2012)
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung CancersScience Translational Medicine, 4
-
H. Isozaki, E. Ichihara, N. Takigawa, K. Ohashi, N. Ochi, Masayuki Yasugi, T. Ninomiya, H. Yamane, K. Hotta, Katsuya Sakai, Kunio Matsumoto, S. Hosokawa, A. Bessho, T. Sendo, M. Tanimoto, K. Kiura (2016)
Non-Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases.Cancer research, 76 6
-
K. Takeuchi, M. Soda, Yuki Togashi, R. Suzuki, S. Sakata, S. Hatano, R. Asaka, W. Hamanaka, H. Ninomiya, H. Uehara, Y. Choi, Y. Satoh, S. Okumura, K. Nakagawa, H. Mano, Y. Ishikawa (2012)
RET, ROS1 and ALK fusions in lung cancerNature Medicine, 18
-
D. Maddalo, Eusebio Manchado, Carla Concepcion, Ciro Bonetti, Joana Vidigal, Yoon-Chi Han, Paul Ogrodowski, A. Crippa, N. Rekhtman, E. Stanchina, S. Lowe, A. Ventura (2014)
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 systemNature, 516
-
(2017)
Lorlatinib in non‐small‐cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open‐label, single‐arm first‐in‐man phase 1 trial, 18
-
S. Gadgeel, L. Gandhi, Gregory Riely, A. Chiappori, H. West, Michele Azada, P. Morcos, Ruey-min Lee, L. Garcia, Li Yu, F. Boisserie, L. Laurenzio, S. Golding, Jotaro Sato, S. Yokoyama, Tomohiro Tanaka, S. Ou (2014)
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.The Lancet. Oncology, 15 10
-
A. Shaw, Dong-Wan Kim, K. Nakagawa, T. Seto, L. Crinò, M. Ahn, T. Pas, B. Besse, B. Solomon, F. Blackhall, Yi-long Wu, Michael Thomas, K. O'Byrne, D. Moro-Sibilot, D. Camidge, T. Mok, V. Hirsh, Gregory Riely, S. Iyer, V. Tassell, A. Polli, K. Wilner, P. Jänne (2013)
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.The New England journal of medicine, 368 25
-
K. Takeuchi, Y. Choi, Yuki Togashi, M. Soda, S. Hatano, K. Inamura, S. Takada, Toshihide Ueno, Y. Yamashita, Y. Satoh, S. Okumura, K. Nakagawa, Y. Ishikawa, H. Mano (2009)
KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung CancerClinical Cancer Research, 15
-
I. Janoueix-Lerosey, D. Lequin, L. Brugières, A. Ribeiro, L. Pontual, V. Combaret, V. Raynal, A. Puisieux, G. Schleiermacher, G. Pierron, D. Valteau‐Couanet, T. Frebourg, J. Michon, S. Lyonnet, J. Amiel, O. Delattre (2008)
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature, 455
-
T. Marsilje, W. Pei, Bei Chen, Wenshuo Lu, T. Uno, Yunho Jin, Tao Jiang, Sungjoon Kim, Nanxin Li, M. Warmuth, Yelena Sarkisova, F. Sun, Auzon Steffy, A. Pferdekamper, Allen Li, S. Joseph, Young Kim, Bo Liu, T. Tuntland, Xiaoming Cui, N. Gray, R. Steensma, Yongqin Wan, Jiqing Jiang, Greg Chopiuk, Jie Li, W. Gordon, Wendy Richmond, Kevin Johnson, Jonathan Chang, T. Groessl, Y. He, Andrew Phimister, Alex Aycinena, Christian Lee, B. Bursulaya, D. Karanewsky, H. Seidel, Jennifer Harris, P. Michellys (2013)
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2Journal of medicinal chemistry, 56 14
-
Akihiro Kogita, Y. Togashi, H. Hayashi, E. Banno, M. Terashima, M. Velasco, K. Sakai, Y. Fujita, S. Tomida, Y. Takeyama, K. Okuno, K. Nakagawa, K. Nishio (2015)
Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer.International journal of oncology, 46 3
-
S. Gettinger, L. Bazhenova, C. Langer, R. Salgia, K. Gold, R. Rosell, A. Shaw, G. Weiss, M. Tugnait, N. Narasimhan, D. Dorer, D. Kerstein, V. Rivera, T. Clackson, F. Haluska, D. Camidge (2016)
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.The Lancet. Oncology, 17 12
-
Phillip Murray, I. Lax, Andrey Reshetnyak, G. Ligon, J. Lillquist, E. Natoli, Xiarong Shi, E. Folta-Stogniew, M. Gunel, Diego Alvarado, J. Schlessinger (2015)
Heparin is an activating ligand of the orphan receptor tyrosine kinase ALKScience Signaling, 8
-
Andrey Reshetnyak, Phillip Murray, Xiarong Shi, Elizabeth Mo, Jyotidarsini Mohanty, Francisco Tomé, Hanwen Bai, M. Gunel, I. Lax, J. Schlessinger (2015)
Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactionsProceedings of the National Academy of Sciences, 112
-
C. Lovly, W. Pao (2012)
Escaping ALK Inhibition: Mechanisms of and Strategies to Overcome ResistanceScience Translational Medicine, 4
-
J. Weiss, C. Xue, T. Benice, L. Xue, S. Morris, J. Raber (2012)
Anaplastic Lymphoma Kinase and Leukocyte Tyrosine Kinase: Functions and genetic interactions in learning, memory and adult neurogenesisPharmacology Biochemistry and Behavior, 100
-
B. Solomon, T. Mok, Dong-Wan Kim, Yi-long Wu, K. Nakagawa, T. Mekhail, E. Felip, F. Cappuzzo, J. Paolini, T. Usari, S. Iyer, A. Reisman, K. Wilner, J. Tursi, F. Blackhall (2014)
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.The New England journal of medicine, 371 23
-
J. Soria, D. Tan, R. Chiari, Yi-long Wu, L. Paz-Ares, J. Wolf, Sarayut Geater, S. Orlov, D. Cortinovis, Chong-Jen Yu, M. Hochmair, A. Cortot, C. Tsai, D. Moro-Sibilot, R. Campelo, T. McCulloch, P. Sen, M. Dugan, Serafino Pantano, F. Branle, C. Massacesi, G. Castro (2017)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 studyThe Lancet, 389
-
T. Iwahara, J. Fujimoto, D. Wen, R. Cupples, N. Bucay, T. Arakawa, S. Mori, B. Ratzkin, Tadashi Yamamoto (1997)
Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous systemOncogene, 14
-
S. Peters, D. Camidge, A. Shaw, S. Gadgeel, J. Ahn, Dong-Wan Kim, S. Ou, M. Pérol, R. Dziadziuszko, R. Rosell, A. Zeaiter, E. Mitry, S. Golding, B. Balas, J. Noé, P. Morcos, T. Mok (2017)
Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung CancerThe New England Journal of Medicine, 377
-
Yuyan Chen, J. Takita, Y. Choi, Motohiro Kato, M. Ohira, M. Sanada, Lili Wang, M. Soda, A. Kikuchi, T. Igarashi, A. Nakagawara, Y. Hayashi, H. Mano, S. Ogawa (2008)
Oncogenic mutations of ALK kinase in neuroblastomaNature, 455
-
L. Friboulet, Nanxin Li, Ryohei Katayama, Christian Lee, J. Gainor, A. Crystal, P. Michellys, M. Awad, N. Yanagitani, Sungjoon Kim, A. Pferdekamper, Jie Li, S. Kasibhatla, F. Sun, Xiuying Sun, S. Hua, P. McNamara, Sidra Mahmood, Elizabeth Lockerman, N. Fujita, M. Nishio, Jennifer Harris, A. Shaw, J. Engelman (2014)
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.Cancer discovery, 4 6
-
A. Crystal, A. Shaw, L. Sequist, L. Friboulet, M. Niederst, Elizabeth Lockerman, R. Frias, J. Gainor, A. Amzallag, Patricia Greninger, Dana Lee, Anuj Kalsy, María Gomez-Caraballo, L. Elamine, Emily Howe, W. Hur, W. Hur, E. Lifshits, Hayley Robinson, Ryohei Katayama, A. Faber, M. Awad, Sridhar Ramaswamy, M. Mino‐Kenudson, A. Iafrate, C. Benes, J. Engelman (2014)
Patient-derived models of acquired resistance can identify effective drug combinations for cancerScience, 346
-
S. Lim, H. Kim, Jong-Seok Lee, K. Lee, Yun-Gyoo Lee, Y. Min, E. Cho, S. Lee, Bongseog Kim, M. Choi, H. Shim, Jin-Haeng Chung, Y. Choi, M. Lee, Maria Kim, Joo‐Hang Kim, Siraj Ali, M. Ahn, B. Cho (2017)
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35 23
-
G. Stoica, Angera Kuo, C. Powers, E. Bowden, E. Sale, A. Riegel, A. Wellstein (2002)
Midkine Binds to Anaplastic Lymphoma Kinase (ALK) and Acts as a Growth Factor for Different Cell Types*The Journal of Biological Chemistry, 277
-
H. Sakamoto, T. Tsukaguchi, Sayuri Hiroshima, Tatsushi Kodama, Takamitsu Kobayashi, T. Fukami, N. Oikawa, Takuo Tsukuda, Nobuya Ishii, Y. Aoki (2011)
CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.Cancer cell, 19 5
-
J. Gainor, D. Tan, T. Pas, B. Solomon, A. Ahmad, C. Lazzari, F. Marinis, G. Spitaleri, Katherine Schultz, L. Friboulet, B. Yeap, J. Engelman, A. Shaw (2015)
Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and CeritinibClinical Cancer Research, 21
-
C. Lovly, J. Heuckmann, E. Stanchina, Heidi Chen, Roman Thomas, C. Liang, W. Pao (2011)
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.Cancer research, 71 14
-
S. Fujita, K. Masago, N. Katakami, Y. Yatabe (2016)
Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 11 6
-
G. Ott, M. Cheng, K. Learn, Jason Wagner, D. Gingrich, Joseph Lisko, M. Curry, E. Mesaros, A. Ghose, M. Quail, W. Wan, Lihui Lu, P. Dobrzanski, Mark Albom, T. Angeles, K. Wells-Knecht, Zeqi Huang, L. Aimone, E. Bruckheimer, N. Anderson, J. Friedman, S. Fernandez, M. Ator, B. Ruggeri, B. Dorsey (2016)
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).Journal of medicinal chemistry, 59 16
-
E. Kwak, Y. Bang, D. Camidge, A. Shaw, B. Solomon, Robert Maki, Sai-Hong Ou, Bruce Dezube, P. Jänne, Daniel, B. Costa, M. Varella-Garcia, W. Kim, Thomas Lynch, P. Fidias, Hannah Stubbs, J. Engelman, V. Lecia, Sequist, Weiwei Tan, L. Gandhi, M. Mino‐Kenudson, Greg Wei, S. Shreeve, M. Ratain, Jeffrey, Settleman, James Christensen, D. Haber, K. Wilner, R. Salgia, Geoffrey Shapiro, J. Clark, A. Iafrate (2010)
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.The New England journal of medicine, 363 18
-
Zongli Zheng, M. Liebers, Boryana Zhelyazkova, Yi Cao, Divya Panditi, Kerry Lynch, Juxiang Chen, Hayley Robinson, H. Shim, J. Chmielecki, W. Pao, J. Engelman, A. Iafrate, Long Le (2014)
Anchored multiplex PCR for targeted next-generation sequencingNature Medicine, 20
-
Azusa Tanimoto, Tadaaki Yamada, S. Nanjo, S. Takeuchi, H. Ebi, K. Kita, Kunio Matsumoto, S. Yano (2014)
Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cellsOncotarget, 5
-
T. Tsuruo, H. Iida, S. Tsukagoshi, Y. Sakurai (1981)
Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.Cancer research, 41 5
- Publisher
- Wiley
- Copyright
- © 2018 Japanese Cancer Association
- eISSN
- 1349-7006
- DOI
- 10.1111/cas.13504
- pmid
- 29336091
- Publisher site
- See Article on Publisher Site
Abstract
Journal
Cancer Science – Wiley
Published: Mar 1, 2018
Keywords: ; ; ; ;